Abstract
Five hyperthyroid patients (two men and three women) with typical features of subacute thyroiditis were treated with sodium ipodate (Oragrafin; 0.5 g, orally daily or every other day) for 15-60 days; the treatment was stopped when both serum T4 and T3 levels were normal. All patients studied demonstrated a prompt normalization of serum T3, improvement in clinical symptoms of hyperthyroidism, and/or weight gain. We observed no side-effects of treatment with sodium ipodate. Our data suggest that sodium ipodate is a safe and effective agent for management of hyperthyroidism in subacute thyroiditis.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Autoantibodies / blood
-
Body Weight / drug effects
-
Female
-
Follow-Up Studies
-
Humans
-
Hyperthyroidism / blood
-
Hyperthyroidism / drug therapy*
-
Hyperthyroidism / etiology
-
Ipodate / therapeutic use*
-
Male
-
Middle Aged
-
Thyroid Gland / immunology
-
Thyroid Gland / metabolism
-
Thyroiditis, Subacute / blood
-
Thyroiditis, Subacute / drug therapy*
-
Thyroiditis, Subacute / immunology
-
Thyrotropin / blood*
-
Thyroxine / blood*
-
Time Factors
-
Triiodothyronine / blood*
Substances
-
Autoantibodies
-
Triiodothyronine
-
Thyrotropin
-
Ipodate
-
Thyroxine